“Renal cell carcinoma (RCC) is the most common malignancy of urogenital system, and patients with RCC may face a poor prognosis. However, limited curable therapeutic options are currently available.
The aim of this study is to investigate the role of Cannabinoid receptor 2 (CB2) in RCC progression.
CB2 expression is functionally related to cellular proliferation, migration, and cell cycle of RCC cells.
Our data suggest that CB2 might be a potential therapeutic target for RCC.”